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ABSTRACT
We studied the role of HLA-matched sibling hematopoietic cell transplantation (HCT) in treating t(8;21) acute
myelogenous leukemia (AML) in first remission. Outcomes of 118 patients receiving HCT and reported to the
Center for International Blood and Marrow Transplant Research were compared with 132 similar patients re-
ceiving chemotherapy selected from8GermanAMLIntergroupmulticenter trials.Characteristics of the cohorts
were similar except that chemotherapy recipients were significantly older. To adjust for time to treatment bias,
outcomes were compared using left-truncated Cox regression models. Transplants were associated with higher
treatment-related mortality (TRM; relative risk [RR] 6.76, 95% confidence interval [CI] 2.95-15.45, P\ .001),
lower relapse (RR 0.47, 95%CI 0.25-0.85,P5 .01), and similar relapse-free survival (P5 .2). Loss of sex chromo-
somes (LOS) in addition to t(8;21) had a negative impact on overall survival (OS) in patients receiving chemother-
apy. Patients without LOS experienced shorter survival after HCT comparing to chemotherapy (RR 3.05,
P 5 .02), whereas patients with LOS had similar survival regardless of postremission therapy. In both cohorts,
white blood cell count (WBC) at diagnosis .25  109/L was associated with a higher relapse risk (RR 5 2.09, P
5 .03), lower relapse-free (RR 5 1.9, P 5 .008), and OS (RR 5 1.91, P 5 .01). In this cohort of patients with
t(8;21) AML, HCT did not improve OS, because reduction of relapse was offset by high TRM. In the group
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188 R. F. Schlenk et al.without LOS, survival after chemotherapy was far superior to HCT. These results suggest that patients with
t(8;21) AMLwithout poor prognostic factors have higher rates of survival after chemotherapy as a post remission
therapy compared to HCT.
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Translocation t(8;21) (q22;q22) (t[8;21]) is found
in 1/3 of karyotypically abnormal and approximately
8% of all patients with acute myeloid leukemia AML
[1]. This translocation is associated with secondary ab-
errations in 60% to 80% of cases, with loss of a sex
chromosome (LOS) being the most frequent [2-4].
At the molecular level this translocation involves
RUNX1 (AML1) on chromosome 21 and CBFA2T1
(ETO) on chromosome 8 [5]. RUNX1 is a member
of the core-binding factor alpha family (CBFa) of tran-
scriptional regulators and, through interaction with
CBFb, allows transcription of genes required for mye-
loid differentiation. The RUNX1/CBFA2T1 fusion
protein acts as a dominant repressor of RUNX1-
dependent transcription.
The role of postremission therapy in acute mylege-
nous leukemia (AML) is to decrease relapse and pro-
long survival. Outcomes after postremission therapy
vary considerably by specific AML subtypes and pres-
ence of poor prognostic factors. Slovak et al. [6], from
the American Intergroup study (SWOG/ECOG), ob-
served superior overall survival (OS) after transplanta-
tion compared to chemotherapy among patients with
favorable risk AML: t(8;21), t(15;17), and inv (16). Con-
versely, both French and German AML Intergroups
showed no difference between hematopoietic stem
cell transplantation (HCT) strategies and intensive
chemotherapy for this group of AML patients [7,8].
Relapse varies substantially according to additional
risk factors within the same cytogentically risk cate-
gories. Leukocytosis at diagnosis is associated with
worse outcomes [9,10], with the French and the Ger-
man AML Intergroup analyses revealing nearly identi-
cal cut points for higher risk category (30  109/L and
25.4  109/L, respectively) [4,7,11]. Additional cyto-
genetic abnormalities also predict treatment outcomes
but less certainly than leukocytosis. LOS in men and
del(9q) are associated with shorter survival outcomes
in patients with t(8;21) [3,4,12,13].
In this study we examined 2 different postremis-
sion strategies for t(8;21) AML in the first complete re-
mission (CR1), namely, intensive chemotherapy with
cytarabine-based regimes, using data from the German
AML Intergroup, and HLA-matched sibling HCT us-
ing data from the Center for International Blood and
Marrow Transplant Research (CIBMTR). Current
practice does not suggest that t(8;21) AML in the
CR1 is an indication for sibling donor HCT. We un-dertook this analysis to determine whether this cur-
rently held practice was evidence based, especially in
the light of known prognostic factors in this specific
type of AML.
MATERIAL AND METHODS
Data Sources
Transplant cohort. The CIBMTR is a voluntary
working group of more than 400 centers worldwide.
Participating centers register basic information on all
consecutive transplant recipients. Comprehensive de-
mographic and clinical data are collected on a repre-
sentative sample of registered patients selected using
a weighted randomization scheme. Patients are fol-
lowed longitudinally, with yearly follow-up.
Computerized checks for errors, physician reviews
of submitted data, and on-site audits of participating
centers ensure the quality of data. Studies utilizing
CIBMTR data are approved by the Medical College
of Wisconsin Internal Review Board.
Chemotherapy cohort. The data from patients
who received chemotherapy were obtained from the
German AML Intergroup database using data from 8
multicenter prospective clinical trials [4]: SHG-Hann-
over-AML-2/95 [14], SHG-Hannover-AML-1/99,
SHG-Dresden-AML-96 [15], AMLSG ULM
AMLHD93 [8], AMLSG ULM AML-HD 98A,
AMLCG92 [16], AMLCG99 [17], and OSHO
AML-96. All trials enrolled AML patients and in-
cluded double-induction chemotherapy followed by
different postremission strategies including different
dose levels of cytarabine-based chemotherapy, autolo-
gous, and allogeneic HCT.
Eligibility Criteria
The study included patients with t(8;21) AML in
morphologic CR1, aged 16 to 60 years, who under-
went an HLA-identical sibling HCT with myeloabla-
tive conditioning regimen reported to the CIBMTR
from 1990 to 2002 or who received chemotherapy in
1 of the German trials noted above from 1993 to
2002. One hundred ninety-seven patients with
t(8;21) AML enrolled in the German trials. Thirty-
one were excluded for not achieving remission, 7 for
not receiving postremission therapy, and 27 for receiv-
ing an allogeneic (n 5 9) or an autologous (n 5 18)
HCT. Thus, 132 patients were eligible for this study.
Among the 124 patients receiving HLA-identical
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CIBMTR, 2 were excluded for receiving reduced-in-
tensity conditioning regimens and 4 from inactive
transplant centers for insufficient post transplant fol-
low-up data, leaving a total of 118 eligible patients,
contributed by 66 centers in 26 countries (Table 1).
Cytogenetic Analysis and Review
All cytogenetic and molecular analyses in the che-
motherapy cohort except for the OSHO trial were per-
formed in central reference laboratories per protocol
requirements. In the OSHO trial, cytogenetic analyses
were required prior to study entry but there was no
central review (n 5 9). The CIBMTR requests infor-
mation on cytogenetic testing performed at diagnosis,
prior to transplantation and at relapse, but not all pa-
tients had these analyses performed. Only cases
reporting the presence of t(8;21) were included. Cyto-
genetic reports were available for review and confirma-
tion for 69 of 118 patients in the transplant cohort.
Descriptions of karyotypic abnormalities adhered to
the International System for Human Cytogenetic No-
menclature [18]. Five patients in the chemotherapy
and 1 patient in the HCT group without evaluable
metaphases had confirmed t(8;21) through AML1/
ETO molecular analysis.
The most frequent additional cytogenetic change
observed in both groups was LOS chromosomes
(2X or 2Y). Three groups were analyzed: t(8;21)
alone, t(8;21) and LOS with or without other cytoge-
netic changes, and t(8;21) with other cytogenetic
changes excluding LOS. Deletion 9q was present in
only a small proportion of patients (chemotherapy, n
5 21 and HCT, n 5 9), precluding separate analysis.
Outcomes
Treatment-related mortality (TRM) was defined
as deaths occurring during the CR1 as calculated by
the cumulative incidence estimate, with relapse as the
competing risk. Patients were censored at time of last
follow-up. Relapse was defined as morphologic leuke-
mia recurrence at any site by the cumulative incidence
estimate, with death in remission as the competing
risk. Patients were censored at death in the CR1 or sur-
viving in continuous CR at last contact. Relapse-free
survival (RFS) and OS were defined, respectively, as
survival in complete CR and survival, with censoring
at last follow-up [19]. For OS, death from any cause
was considered an event. For RFS (ie, treatment fail-
ure), relapse or death was considered an event.
Statistical Analysis
Variables related to patient and disease character-
istics were compared between groups using the chi-
square statistic or Fishers exact test, if appropriate,
for categoric variables and the Kruskal-Wallis testfor continuous variables. The median follow-up time
was calculated utilizing the Kaplan-Meier estimate
for the censoring distribution.
When comparing outcomes of transplant versus
nontransplant groups, differences in time to treatment
and differences in patient baseline characteristics are
potential sources of bias and require appropriate ad-
justments. As transplant recipients must survive long
enough to undergo transplantation, they may repre-
sent population with inherently better outcome. To
address this potential bias, left-truncated Cox regres-
sion models and left-truncated cumulative incidence
estimates were used. At each time point in this model,
the risk set in the chemotherapy cohort consisted of all
patients, whereas the risk set in the transplant cohort
included only those whose waiting time to transplant
was less than this time point [20].
To adjust for differences in baseline characteris-
tics, multivariate Cox proportional hazards regression
models were used [21]. First, associations between
each outcome and potential prognostic variables
(listed in Table 2) were evaluated using a stepwise ap-
proach. Variables significantly associated with each
outcome event (P \ .05) were included as covariate
factors in the subsequent comparisons. The propor-
tionality assumption of the Cox model was tested by
adding separately for each outcome event a time-de-
pendent covariate for each of the covariates tested.
Presence of LOS in the OS model was the only variable
demonstrating significant interaction with type of
postremission therapy. Adjusted probabilities of RFS
and OS were then generated from the final Cox models
stratified on postremission therapy. Results were ex-
pressed as relative risks (RR) of each outcome after
transplantation versus after chemotherapy. P-values
are 2-sided. Analyses were performed using SAS soft-
ware, version 9.2 (SAS Institute, Cary, NC).
RESULTS
Patient Characteristics
Table 1 shows patient, disease, and treatment-re-
lated characteristics by postremission therapy. Trans-
plant recipients were younger than chemotherapy
recipients (median age 32 versus 42 years, P\ .001).
We considered patients as having high-risk leukocyto-
sis, if their WBC count at diagnosis was .25  109/L
[4]. Cytogenetic abnormalities detected in addition to
the t(8;21) were frequently observed in both groups.
Fifty-two percent of HCT patients received TBI-based
conditioning regimens and 88% received bone marrow
grafts. None of the HCT recipients received donor lym-
phocyte infusions either as a planned therapy or for re-
current leukemia. Most transplants were performed
prior to 1994; consequently, median follow-up times
of survivors were 48 and 94 months after chemotherapy
and HCT, respectively. Nevertheless, 66% of
190 R. F. Schlenk et al.Table 1. Characteristics of Patients 16-60 years of Age with t(8;21) AML in First Complete Remission Who Either Received a Cytarabine-Based
Chemotherapy or an HLA-Identical Sibling Transplant
Chemotherapy Transplant
Characteristics of Patients N Eval N (%) N Eval N (%) P-Value
Number of patients 132 118
Number of multicenter trials*/ centers 8 66
Age at first CR, median (range), years 132 42 (17-60) 118 32 (16-52) \.001
Age at first CR 132 118 \.001
16-19 y 6 (5) 10 (8)
20-29 y 18 (14) 44 (37)
30-39 y 27 (20) 38 (32)
40-49 y 44 (33) 23 (20)
$50 y 37 (28) 3 (3)
Male sex 132 81 (61) 118 73 (62) .94
FAB subtype 129 118 .09
M1 6 (5) 10 (9)
M2 111 (86) 92 (78)
M3 3 (2) 0
M4 7 (5) 12 (10)
RAEBT 1 (1) 0
Other 1 (1) 4 (3)
WBC at diagnosis, 109/L, median
(range)
130 9 (1-152) 114 11 (2-260) .17
WBC at diagnosis .25.4  109/L 130 21 (16) 114 24 (21) .32
Year of diagnosis 132 118 \.001
1989-1990 0 19 (16)
1991-1992 0 30 (26)
1993-1994 1 (\1) 21 (18)
1995-1996 26 (20) 18 (15)
1997-1998 34 (26) 12 (10)
1999-2000 33 (25) 10 (8)
2001-2002 38 (29) 8 (7)
Cytogenetics 127 118
t(8;21) as the sole change 43 (34) 53 (45) .30
Additional LOS 58 (46) 48 (41)
2X ± other 50 19 (38) 45 16 (35)
2Y ± other 77 39 (50) 73 32 (44)
Other 26 (20) 17 (14)
Blast in bone marrow, median % (range) 123 60 (7-100) 104 59 (8-100) .32
Extramedullary disease at diagnosis 130 8 (6) 118 14 (12) .11
Consolidation therapy 132 117 —
Standard Ara-C 2 (2) 42 (36)
Intermediate Ara-C 25 (19) 0
High-dose Ara-C 105 (79) 30 (25)
Other consolidation 0 23 (20)
None 0 22 (19)
Number of consolidation cycles 132 118 —
0 0 22 (19)
1 3 (2) 39 (33)
2 52 (40) 21 (18)
3 77 (58) 7 (6)
4 0 2 (1)
Missing 0 27 (23)
Conditioning regimen NA 118 —
Bu 1 Cy ± other 54 (46)
Cy 1 TBI ± other 50 (42)
TBI ± other 12 (10)
Other† 2 (2)
Duration of postremission treatment,
months
132 3 (\1-14) NA —
Time from first CR to transplant, months NA 118 3 (\1-12) —
Time from diagnosis to last treatment/
HCT, months
132 5 (1-16) 118 5 (2-16) .67
Donor-recipient sex match NA 118 —
(Continued )
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Chemotherapy Transplant
Characteristics of Patients N Eval N (%) N Eval N (%) P-Value
Male donor/male recipient 31 (26)
Male donor/female recipient 24 (20)
Female donor/male recipient 42 (36)
Female donor/female recipient 21 (18)
CMV status NA 111 —
Donor (1)/recipient (1) 47 (42)
Donor (1)/recipient (2) 12 (11)
Donor (2)/recipient (1) 25 (23)
Donor (2)/recipient (2) 27 (24)
Graft type NA 118 —
Bone marrow 104 (88)
Peripheral blood 14 (12)
GVHD prophylaxis NA 118 —
CsA 1 MTX ± other 92 (78)
CsA ± other, tacrolimus ± other 17 (14)
T-cell depletion ± other 9 (8)
Median follow-up of survivors, months 43 (2-108) 77 (14-178)
EVAL indicates evaluable; FAB, French-American-British classification; WBC, white blood cell count; CR, complete remission; Bu, busulfan;
Cy, cyclophosphamide; TBI, total body irradiation; CMV, cytomegalovirus; CsA, cyclosporine; MTX, methotrexate; LOS, loss of sex chro-
mosome; HCT, hematopoietic stem cell transplant.
*SHG-Hannover-AML-2/95 (n5 22); SHG-Hannover-AML-1/99 (n5 7); AMLHD93 (n5 13); AMLHD98A (n5 26); AMLCG92 (n5 15);
AMLCG99 (n 5 13); OSHO-AML-96 (n 5 9); SHG-D (n 5 27).
†Other conditioning regimen were: busulfan 1 melphalan (1); bleomycin 1 cyclophosphamide (1).chemotherapy and 87% of transplant recipients
were followed for$5 years and the completeness of fol-
low-up (the ratio of the sum of the observed follow-up
time to the sum of the potential follow-up time for all pa-
tients in the study) [22] was 86% for both treatment
groups. The rate of grade II-IV acute graft-versus-host
disease (aGVHD) at day 100 after HCT was 9% (95%
confidence intervals [CI] 5%-15%] and chronic
GVHD (cGVHD) at 1 and 3 years were 27% (95% CI
19%-35%) and 37% (95% CI 29%-46%).
TRM
Risks of TRM were significantly higher after HCT
than after chemotherapy (Table 3). The 5-year cumu-
lative incidences of TRM were 6% (95% CI 2%-11%)
and 32% (95% CI 22%-44%) after chemotherapy and
HCT, respectively (Figure 1).
Leukemia Relapse
Risks of leukemia relapse were significantly lower
after HCT than after chemotherapy (Table 3). The 5-
year probabilities of relapse was 29% (95% CI 21%-
37%) and 14% (95% CI 8%-21%) after chemotherapy
and HCT, respectively (P 5 .005) (Figure 2). Risks of
relapse were significantly higher in patients with WBC
.25.4  109/L at diagnosis in both cohorts (Table 3).
RFS
Risks of treatment failure (relapse or death) were
similar after chemotherapy and HCT (Table 3). The
5-year probabilities of RFS were 64% (95% CI 53%-73%) and 55% (95%CI 45%-65%) after chemother-
apy and HCT, respectively (p 5 .2) (Figure 3). Risks
Table 2. Variables Tested in Cox Proportional Hazards RegressionModels
Main Effect Variable:*
Postremission treatment: cytarabine-based chemotherapy versus
HLA-identical sibling transplant
Patient-related variables:
Age at first CR: continuous
Sex: female versus male
Disease-related variables at diagnosis:
WBC at diagnosis: #25.4  109/L versus .25.4  109/L versus
missing
Blast in BM: $60% versus 60% versus unknown
Year of diagnosis: continuous
Additional cytogenetics abnormalities: t(8;21) alone versus t(8;21)
and LOS ± other versus t(8;21) and other additional not LOS
Disease-related variables at transplant:
Extramedullary disease at diagnosis: yes versus no
Time from diagnosis to first CR
Chemotherapy-related:
German AML Intergroup clinical trial
Treatment-related (for transplant group only):
Conditioning regimen: Bu 1 Cy ± other versus Cy 1 TBI ± other
versus others
Donor age
Donor-recipient sex match: match versus mismatch
Donor-recipient CMV status: 2/2 versus others
Graft type: bone marrow versus peripheral blood
CR indicates complete remission; WBC, white blood cell count;
BM, bone marrow; LOS, loss of sex chromosome; Bu, busulfan;
Cy, cyclophosphamide; TBI, total body irradiation; CMV, cyto-
megalovirus.
*Included in all models.
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nostic WBC .25  109/L in both cohorts (Table 3).
OS
OS after HCT versus chemotherapy differed in the
presence or absence of LOS in addition to t(8;21).
Risks of overall mortality were significantly higher
after HCT than after chemotherapy in patients with
t(8;21) and no LOS; risks of overall mortality were
similar after HCT and chemotherapy in patients with
t(8;21) and LOS (Figure 4). WBC .25.4  109/L
Table 3. Relative Risk of Treatment-Related Mortality, Relapse,
Leukemia-Free Survival, and Overall Survival in Patients Receiving
HCT versus Chemotherapy for Postremission Treatment
Outcome N Evaluable
Relative Risk
(95% Confidence
Interval) P-Value
Treatment related
mortality
Chemotherapy 132 1.00*
Transplant 118 6.76 (2.95-15.45) \.001
Other significant
covariates:†
Blast in bone
marrow
\60 % 109 1.00*
$60% 118 2.64 (2.95-15.45) .005
Relapse
Chemotherapy 132 1.00*
Transplant 118 0.47 (0.25-0.85) .014
Other significant
covariates:
WBC at diagnosis
#25  109/L 199 1.00*
.25  109/L 45 2.09 (1.09-4.04) .028
Relapse-free
survival‡
Chemotherapy 132 1.00*
Transplant 118 1.29 (0.84-1.98) .24
Other significant
covariates:
WBC at diagnosis
#25  109/L 199 1.00*
.25  109/L 45 1.90 (1.18-3.05) .008
Overall survival§
No LOS
Chemotherapy 69 1.00*
Transplant 70 3.05 (1.51-6.15) .002
LOS
Chemotherapy 58 1.00*
Transplant 48 0.90 (0.47-1.70) .74
WBC at diagnosis
#25  109/L 199 1.00*
.25  109/L 45 1.91 (1.16-3.15) .012
LOS indicates loss of sex chromosome.
*Reference group.
†WBC was not a significant covariate (RR 5 1.52, 95% CI 0.81-
2.86, P 5 .19).
‡Relative risk of relapse or death.
§Relative risk of death.was associated with higher risk of overall mortality after
both chemotherapy and HCT (Table 3).
Causes of Death
The most common cause of death in both treat-
ment groups was recurrent leukemia, accounting for
70% of deaths after chemotherapy and 24% of deaths
after HCT. Nonrelapse causes of death after chemo-
therapy included infection (21%), organ failure (3%),
secondary malignancy (3%), and other causes (3%).
Nonrelapse causes of death after HCT were infection
(16%), interstitial pneumonitis (6%), acute respiratory
distress syndrome (8%), aGVHD (2%), cGVHD
(10%), interstitial pneumonitis and GVHD (6%), or-
gan failure (10%), secondary malignancy (6%), hem-
orrhage (4%), and other causes (2%). The cause of
death was unknown for 3 patients (6%) in the HCT co-
hort.
DISCUSSION
This study shows that HLA-matched sibling HCT
for t(8;21) AML in the CR1 for patients between 16
and 60 years is associated with lower relapse rates,
Figure 1. Cumulative incidence of TRM after chemotherapy and
HLA-matched sibling hematopoietic stem cell transplant for pa-
tients with t(8;21) AML in CR1, by postremission treatment.
Figure 2. Cumulative incidence of relapse after chemotherapy and
HLA-matched sibling hematopoietic stem cell transplant for pa-
tients with t(8;21) AML in CR1, by postremission treatment.
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bine-based postremission chemotherapy. This is con-
sistent with reports of unselected groups of AML
patients treated in the CR1. Reported relapse rates af-
ter allogeneic HCT for AML in CR1 range from 24%
to 37% [23-26] compared to much higher rates after
chemotherapy (36%-60%) [23-27]. This advantage
(ie, fewer relapses after HCT) does not always trans-
late into longer RFS or OS because of higher rates of
TRM after HCT. We observed 1-year TRM rates of
23% after HCT, compared to 4% after chemotherapy.
Most transplants were performed in the early 1990s;
however, the year of transplantation did not signifi-
cantly impact the rate of TRM. Despite changes in
transplant practice in the last decade, TRM remains
a major challenge in transplantation. The majority of
patients in the HCT cohort received bone marrow
grafts, which differs from the current practice of utiliz-
ing mobilized peripheral blood stem cells (PBSC) [28].
The selection of graft source is likely to influence he-
matopoietic recovery and incidence of cGVHD. How-
ever, in patients with AML in CR1, rates of TRM are
similar after bone marrow and peripheral blood stem
cells transplants [29-32].
The MRC 10 prospectively compared allogeneic
HCT with chemotherapy allocating patients with
a matched sibling donor to HCT (biologic assign-
ment) [33]. Patients within the favorable risk category
had similar rates of leukemia-free and OS, regardless
of donor availability. This observation and the overall
favorable responses with standard dose chemotherapy
led to recommendations against HCT for patients
with favorable risk AML in CR1. In contrast, the
American Intergroup (SWOG/ECOG) performed
a similar subset analysis by postremission therapy
and showed better survival in favorable risk patients
undergoing either autologous or allogeneic HCT ver-
sus those receiving chemotherapy [6]. Importantly, de-
spite large numbers of patients in these landmark
studies, the groups with specific cytogenetic changes
were small and imbalances between comparison
Figure 3. Adjusted probability of RFS after chemotherapy and
HLA-matched sibling hematopoietic stem cell transplant for pa-
tients with t(8;21) AML in CR1, by postremission treatment.groups become significant. The French AML Inter-
group analysis of t(8;21) AML demonstrated similar
rates of leukemia-free survival with allogeneic HCT
and chemotherapy. Thirty-seven of 154 patients in
the French study underwent HLA-matched sibling
HCT and 5-year probabilities of LFS were 56% and
52% for the transplant and chemotherapy groups, re-
spectively [11].
Treatment outcomes after chemotherapy or HCT
in patients with t(8;21) and additional cytogenetic ab-
normalities are mixed. The MRC and SWOG/ECOG
cytogenetic classifications addressed this issue differ-
ently. The MRC included t(8;21) plus any additional
changes in the favorable risk group because a separate
analysis showed no significant impact of additional cy-
togenetic abnormalities on survival. In contrast,
SWOG/ECOG excluded cases with cytogenetic ab-
normalities in addition to t(8;21) from the favorable
risk group. The current study showed LOS to be an
important predictor of overall mortality when present
in addition to t(8;21) in patients receiving chemother-
apy. Deletion of chromosome Y was the most frequent
LOS and the main factor associated with poorer sur-
vival. Subset analysis on a group of patients with 2X
(chemotherapy, n 5 18 and HCT, n 5 16) did not
show the same association. As the number of patients
with 2X was small, this interpretation deserves cau-
tion. Furthermore, the presence of additional cytoge-
netic abnormalities to t(8;21) other than LOS did not
affect any outcomes analyzed, and thus were combined
to the group of patients with t(8;21) as a sole cytoge-
netic abnormality. Patients with t(8;21) alone or
t(8;21) with additional cytogenetic abnormalities other
than LOS had longer survival after chemotherapy than
HCT, whereas among those with LOS, there was no
significant difference in survival after chemotherapy
or HCT. These findings contrast other reports
[3,11]. The French Intergroup trial, in which 43% of
patients had LOS and 8% had del(9q), showed no sig-
nificant impact of these abnormalities on survival. A
Figure 4. Adjusted probability of OS after chemotherapy and HLA-
matched sibling hematopoietic stem cell transplant for patients with
t(8;21) AML in CR1, by postremission treatment and presence of sex
chromosome.
194 R. F. Schlenk et al.CALGB analysis of CBF-AML identified 69% with
cytogenetic abnormalities in addition to t(8;21), of
which 90% were LOS and 17.4% del(9q). LOS did
not impact survival, although in a subset of non-White
patients, the presence of del(9q) was associated with
longer OS. These discrepancies may represent inher-
ent differences in study populations and methods of
analyses. In the French study, the subset analysis did
not specify additional cytogenetic changes among
treatment groups. The majority of patients (61%) in
the CALGB study presented with additional LOS
and the 5-year probability of OS for t(8;21) AML pa-
tients was 46% (95% CI 37%-55%). This survival
probability is similar to the chemotherapy cohort
with additional LOS (55%, 95% CI 41%-69%) from
our study. Small numbers of patients with normal sex
chromosomes in the CALGB study may explain why
LOS had no detectable impact on survival. Appelbaum
et al. [2] also analyzed the effect of additional cytoge-
netic changes in the outcome of patients with t(8;21)
AML. The most common additional abnormality
was LOS, and most patients received chemotherapy
as postremission therapy. Neither LOS nor del(9q)
were significantly associated with OS or any other out-
comes. Patients with trisomy 8 or with 3 or more cyto-
genetic abnormalities had worse survival [2]. The
results on the impact of additional cytogenetic abnor-
malities to t(8;21) are conflicting, and represent the
heterogeneity of this patient population. More impor-
tantly, this illustrates that background molecular fac-
tors such as c-KIT expression and others may play
a greater prognostic role; the presence or absence of
certain cytogenetic markers may reveal to be more as
confounders than biologically relevant.
In our study, despite the association of LOS with
lower survival in the chemotherapy cohort, it was not
significantly associated with TRM, relapse, or RFS.
This might be explained by poor survival postrelapse
of patients with LOS. The CALGB study and others
demonstrated shorter postrelapse survival in patients
with t(8;21) compared to those with inv(16) [2,3]. A
German meta-analysis also demonstrated shorter
postrelapse survival for patients with t(8;21) and
LOS [4]. Whether this represents an effect of LOS
or an inherent characteristic of t(8;21) AML remains
undetermined.
Extreme leukocytosis at diagnosis, although un-
common in t(8;21) AML, is considered a poor prognos-
tic factor. Several studies, including this analysis,
confirmed the adverse impact of leukocytosis and
higher marrow blast percentage on treatment outcome
[2,9,10]. Our study demonstrated that leukocytosis was
associated with higher relapse rates, shorter RFS, and
shorter OS irrespective of postremission therapy. A
high percent of blasts in the bone marrow at diagnosis
was associated with the worse TRM. Both leukocytosis
and percent marrow blasts reflect disease burden. Theassociation between high disease burden and TRM is
unclear. Other reports showed an association between
percent of bone marrow blast at diagnosis and lower
CR rates after induction therapy in t(8;21) AML
[3,11]. The association of leukocytosis and survival in
CBF AML is likely to be explained by overexpression
of tyrosine kinase genes related to AML1/ETO.
Gain-of-function mutations of c-KIT are associated
with high disease burden at diagnosis and significantly
impact on survival because of high relapse rates [34-36].
In summary, we report a large comparison of
postremission therapy in a homogenous population
of AML with t(8;21). We acknowledge potential
biases, which may affect the outcomes described.
The chemotherapy group includes participants in
several clinical trials, and patient accrual was deter-
mined by trial specific eligibility criteria. Although
all received cytarabine-based chemotherapy, which
was administered in a spectrum of doses along
with other antileukemic agents, the chemotherapy
regimens considered in regression models did not
influence any of the endpoints studied. Furthemore,
the chemotherapy regimens used as postremission
therapy differs from the 4 cycles of high-dose cytar-
abine (HiDAC) consolidation commonly utilized in
current clinical practice in North America. Despite
the results from the CALGB study on HiDAC on
this patient population being similar to the chemo-
therapy group [37], such differences in practice
should be considered. For the HCT group, the de-
cision to transplant and all aspects of transplant
procedure (ie, conditioning regimen, GVHD pro-
phylaxis, donor selection) were at the discretion of
the transplant center and reflect routine clinical
transplant practices. HCT-related variables were
tested in the regression model and did not affect
the comparisons with chemotherapy. Last, we com-
bined leukocytosis and LOS to assess the impact of
both significant covariates on survival; however, the
groups with both prognostic factors were too small
for a meaningful comparison, and thus it was omit-
ted from the analysis.
AML with t(8;21) is regarded as favorable risk
based on response to initial therapy and longer OS.
This study confirms that cytarabine-based chemother-
apy offers results similar or better than HLA-matched
sibling HCT in first remission. LOS negatively af-
fected survival in patients who received chemotherapy
as postremission therapy, but survival was still similar
to that achieved with HCT. In patients with t(8;21)
but without LOS, OS was longer after chemotherapy
compared to HCT. Higher WBC counts at diagnosis
were associated with worse outcomes after both che-
motherapy and HCT. Selection of the best postremis-
sion therapy for patients with t(8;21) and poor
prognostic features would be best addressed in a risk-
adapted clinical trial.
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